What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations
Affiliation
Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA;Issue Date
2018
Metadata
Show full item recordAbstract
Clinical trial data forms the foundation of how we treat men with metastatic prostate cancer who are initiating therapy. However, clinical trial data does not answer everything; hence, good clinical practice, pragmatism, and occasionally extrapolation drives how we manage these patients. Fortunately, multiple international guideline committees meet regularly and offer clinical guidance. In this mini-review, we focus on the United States National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology (EAU) recommendations for the initial treatment of metastatic prostate cancer.Citation
Yu EY, Gillessen S, Mottet N. What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations. European Urology Focus [Internet]. 2018 Oct.Journal
Eur Urol FocusDOI
10.1016/j.euf.2018.09.015PubMed ID
30287277Additional Links
https://dx.doi.org/10.1016/j.euf.2018.09.015Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.euf.2018.09.015